<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02485873</url>
  </required_header>
  <id_info>
    <org_study_id>18073</org_study_id>
    <secondary_id>DBOX 2014/00799</secondary_id>
    <nct_id>NCT02485873</nct_id>
  </id_info>
  <brief_title>Real-Life Evidence on Stroke Prevention in SPAF</brief_title>
  <acronym>RELIEF</acronym>
  <official_title>REal-LIfe Evidence on Stroke Prevention in Patients With Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To obtain a better understanding on the comparative effectiveness of rivaroxaban and vitamin
      K antagonists (VKA) for stroke prevention in patients with non-valvular atrial fibrillation
      (SPAF) in a real-life setting
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first occurrence of any of the following: Ischemic stroke (IS), Transient ischemic attack (TIA), Intracerebral hemorrhage (IH), Other non-traumatic intracranial hemorrhage including subdural hemorrhage, Myocardial infarction (MI)</measure>
    <time_frame>Within 1 year after treatment start</time_frame>
    <description>Composite cardiovascular endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first occurrence of IS</measure>
    <time_frame>Within 1 year after treatment start</time_frame>
    <description>Single cardiovascular event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first occurrence of TIA</measure>
    <time_frame>Within 1 year after treatment start</time_frame>
    <description>Single cardiovascular event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first occurrence of IH</measure>
    <time_frame>Within 1 year after treatment start</time_frame>
    <description>Single cardiovascular event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first occurrence of Other non-traumatic intracranial hemorrhage including subdural hemorrhage</measure>
    <time_frame>Within 1 year after treatment start</time_frame>
    <description>Single cardiovascular event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first occurrence of MI</measure>
    <time_frame>Within 1 year after treatment start</time_frame>
    <description>Single cardiovascular event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence density in study population of IS</measure>
    <time_frame>Within 1 year after treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence density in study population of TIA</measure>
    <time_frame>Within 1 year after treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence density in study population of IH</measure>
    <time_frame>Within 1 year after treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence density in study population of Other non-traumatic intracranial hemorrhage including subdural hemorrhage</measure>
    <time_frame>Within 1 year after treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence density in study population of MI</measure>
    <time_frame>Within 1 year after treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence density in study population of any of the following: IS, TIA, IH, Other non-traumatic intracranial hemorrhage including subdural hemorrhage, MI</measure>
    <time_frame>Within 1 year after treatment start</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">8607</enrollment>
  <condition>Atrial Fibrillation (Prevention of Stroke)</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <description>Non-valvular Atrial Fibrillation (NVAF) patients who were initiated on rivaroxaban for stroke prevention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin K antagonists (VKA)</arm_group_label>
    <description>NVAF patients who were initiated on VKA (predominately phenprocoumon in Germany) for stroke prevention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban (Xarelto, BAY59-7939)</intervention_name>
    <description>As prescribed by treating physicians</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin K antagonists</intervention_name>
    <description>As prescribed by treating physicians</description>
    <arm_group_label>Vitamin K antagonists (VKA)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with non-valvular atrial fibrillation (NVAF)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥18 years on the day of the first prescription of the study drug (= index date)
             during study selection window

          -  Diagnosis of NVAF on start date of study or anytime during 365 days before this date

          -  Availability of follow-up at least 180 days after the date of the first prescription
             of study drug within selection window of study (exposure start date)

          -  Evidence of patient activity in the database during 90 days before the date of the
             first prescription of target drug within selection window.

        Exclusion Criteria:

          -  Patients with valvular AF

          -  Prescriptions of Oral Anticoagulants (OACs): VKA, Dabigatran, Rivaroxaban before index
             date

          -  Prescription of more than one OAC on the index date or switch to another OAC during
             the follow-up period

          -  Prescriptions of &lt; 15mg rivaroxaban at index date or during the follow-up period for
             patients in rivaroxaban cohort
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2015</study_first_submitted>
  <study_first_submitted_qc>June 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2015</study_first_posted>
  <last_update_submitted>November 10, 2015</last_update_submitted>
  <last_update_submitted_qc>November 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-valvular atrial fibrillation (NVAF)</keyword>
  <keyword>Pevention</keyword>
  <keyword>Stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

